Sionna Therapeutics, Inc. - 8-K Filing
Sionna Therapeutics announced a restructuring plan with $6.4M in charges, executive role changes, and plans for a dual combination drug's Phase 2a trial. (Items: 2.05 Costs Associated with Exit or Disposal Activities, 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $SION